Reference

1. Caprez, J., Rahim, U., Ansari, A., Lodhi, M. U., & Rahim, M. (2018). Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? Cureus. https://doi.org/10.7759/cureus.2397
2. Kwakman, J. J., Elshot, Y. S., Punt, C. J., & Koopman, M. (2020). Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncology Reviews, 14(1). https://doi.org/10.4081/oncol.2020.442
3. Chen, M., Chen, J., Peng, X., Xu, Z., Shao, J., Zhu, Y., Li, G., Zhu, H., Yang, B., Luo, P., & He, Q. (2017). The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environmental Toxicology and Pharmacology, 49, 81–88. https://doi.org/10.1016/j.etap.2016.12.001
4. de Queiroz MVR, de Medeiros ACTR, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. Ecancermedicalscience. 2022 May 16;16:1390. doi: 10.3332/ecancer.2022.1390. PMID: 35919225; PMCID: PMC9300399.
5. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225–34.
6. Lee, S., Kim, H., Hwang, S., Kim, Y. J., Nam, S., & Kim, B. (2007). Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report. Korean Journal of Internal Medicine, 22(2), 109. https://doi.org/10.3904/kjim.2007.22.2.109
7. Kataria, P., Kendre, P., Patel, A., Tahiliani, N., Bhargav, V., & Parekh, H. (2018). Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_547_17
8. Saif MW, Sandoval A. Hand-and-Foot syndrome in an African American Patient treated with Capecitabine with normal DPD activity: Is there an ethnic disparity? Cutan Ocul Toxicol. 2008;27:311–5. [PubMed] [Google Scholar] [Ref list]